Latest Halichondrin B Stories
Eisai Demonstrates Commitment to Patients with Rare Cancers WOODCLIFF LAKE, N.J., Feb. 25, 2015 /PRNewswire/ -- Eisai Inc.
FOR U.S. MEDIA ONLY WOODCLIFF LAKE, N.J., Dec.
Tokyo, July 3, 2014 - (JCN Newswire) - Eisai Co., Ltd.
Indication of Anticancer Agent Halaven for Use in Earlier-Line Treatment of Advanced Breast Cancer Tokyo, May 27, 2014 - (JCN Newswire)
Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc.
Patient Recruitment Now Underway at Treatment Centers Across the United States WOODCLIFF LAKE, N.J., Feb. 27, 2014 /PRNewswire/ -- Eisai Inc.
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits.
- Partnership Based on Open Innovation That Leverages Eisai's Natural Product Chemistry-Based Drug Discovery Platform -Tokyo, July 17, 2012 - (JCN Newswire) - Eisai Co., Ltd.
- Withering but not falling off, as a blossom that persists on a twig after flowering.